Fundraising FoxAzevan
1 known investors
Find your way into Azevan
Sign up to see every warm intro you have to Azevan
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Azevan team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.
Founders & leadership
NG
Neal G. SimonChief Executive Officer & Director
Investors · 1
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $501.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $3.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $141.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $349.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $226.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2002 | $498.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2002 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Azevan do?
- Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.
- Who founded Azevan?
- Azevan was founded by Neal G. Simon.
- Who are Azevan's investors?
- Azevan's investors include Scientific Health Development.